Home news Influenza Vaccine Market Demand in United States 2016 to 2022

Influenza Vaccine Market Demand in United States 2016 to 2022

84
SHARE

United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022.

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It provides essential insights into United States influenza vaccine market and forecast. It covers vaccination pattern, doses distribution, production and offers a clear view of the regulatory landscape. Additionally, the report includes insight of clinical trials, pipeline and promising vaccines in United States influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.

The report concludes with the profiles of major players in the influenza vaccine market such as Sanofi Pasteur, GSK, Seqirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The report also entails major drivers and barriers of influenza vaccine market.

Request sample copy of this report: https://www.marketinsightsreports.com/reports/0718914/united-states-influenza-vaccine-market-vaccination-analysis-distribution-production-pipeline-insights-clinical-trials-deals-type-regulatory-price-trends-competitive-strategies-and-forecast-2016-to-2022/inquiry               

Major and Promising Vaccine covered in the report are as follows:

  • Fluzone High–Dose
  • Fluzone Quadrivalent
  • Intradermal (ID) Trivalent
  • Vaxigrip
  • Fluarix Quadrivalent
  • Flulaval Quadrivalent
  • Fluenz Tetra
  • FluMist Quadrivalent
  • Flublok
  • VN–100
  • M–001
  • VAX–2012Q
  • TAK – 850
  • Flucelvax Quadrivalent
  • Afluria Quadrivalent
  • Agrippal
  • Fluad
  • Fluvirin
  • Fluvax

Key Companies Covered in the Report are as follows:

  • Sanofi Pasteur
  • GlaxoSmithKline(GSK)
  • Seqirus
  • AstraZenecca
  • Protein Sciences Corporation
  • Novavax
  • Daiichi–Sankyo
  • Mitsubishi Tanabe Pharma
  • BiondVax Pharmaceuticals Ltd
  • VaxInnate

Purchase a copy of this report: https://www.marketinsightsreports.com/report/purchase/0718914?mode=su

Preview of Tables and Figures from the report:-

  • United States – Adult Influenza Vaccine Price, 2016 – 2017
  • United States – Flu Vaccine Production, Supply, and Allocation
  • Total Percentage of Flu Vaccines Released by Week,2016 – 2017
  • Total Percentage of Flu Vaccines Released by Week,2015 – 2016
  • Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2005 – 2016
  • United States – Influenza Vaccine Market (Million US$),2010 – 2015
  • United States – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
  • Sanofi Pasteur – Forecast for Influenza Vaccine Net Sales (Million US$),2016 – 2022
  • GSK – Influenza Vaccine Net Sales (Million US$),2011 – 2015
  • GSK – Forecast for Influenza Vaccine Net Sales (Million US$),2016 – 2022

 For more information please Contact: sales@marketinsightsreports.com / +1 (704) 266-3234

LEAVE A REPLY

Please enter your comment!
Please enter your name here